Visual correction in childhood aphakia


Early surgical intervention and adequate orthoptic therapy are important when dealing with children who have undergone cataract surgery. A pseudophakic implant represents an effective solution for the management of aphakic children; a multifocal IOL can provide additional correction, without hindering quality of vision. Here, Klaus Weber, MD provides a brief overview of the incidence, causes and management of childhood cataract, and recommends potential avenues of treatment for the visual rehabilitation of paediatric patients with aphakia.

How common is it?

In developed countries, congenital cataract occurs at a frequency of 0.3 – 0.9%, whilst this complication represents the main cause of potential visual loss in childhood in less developed countries. Overall, the congenital cataract and cataract in childhood - both bilateral and unilateral - lead to distinct visual deprivation.

Dense congenital cataracts and childhood trauma invariably lead to deprivational amblyopia in childhood, with IOL implantation and/or a prescription of binocular or progressive glasses being the current recommendation in children over the age of two years. In order to achieve good functional results, however, early surgical treatment and occlusion therapy are essential to prevent the development of amblyopia in this patient population. In my opinion, orthoptic control, regular check-ups and correction of refractive errors by skiaskopy are mandatory aspects of treatment.

How should we be treating it?

Glasses present a feasible option for the correction of refractive errors in children; however, they are only effective in children with bilateral aphakia, and drawbacks include the weight and the cosmetic appearance of the glasses, prismatic distortion and visual field constriction. Currently, contact lenses are most frequently recommended for visual correction of childhood aphakia. These should be fitted immediately after cataract surgery ensuring refraction is adapted to the action range of the infant (approximately arm's length). Regular six to 12 month check-ups are also advisable because of eyeball growth and accompanying alterations in lens power.

In my opinion, IOL implantation should also be considered in children over the age of two years.

When considering monofocal IOLs, power calculation of the lenses should be done in the range of hyperopia with compensation by glasses or piggyback IOL implantation. IOLs > 40 D are generally required in order to achieve "playing distance" vision (approximately 30 cm).

Second generation multifocal IOLs, like the ReZoom IOL (AMO), are a good alternative to the monofocal lenses because they are associated with greater steroptic, uncorrected and distance-corrected visual outcomes. Furthermore, visual performance after lensectomy is better in eyes that had been treated for bilateral cataracts compared with unilateral cataracts with the multifocal lenses.

In the past, IOLs were considered as a good alternative for the treatment of unilateral cataract; however, postoperative irritations and the issues relating to eyeball growth have hindered their widespread use. Today, IOL implantation is a feasible treatment option for visual rehabilitation in congenital cataract, particularly in older children. Many studies have certainly advocated the use of the multifocal IOLs in this patient population1-6 and, although contact lenses present an adequate treatment approach, especially in the younger child, employment of the new generation of multifocal lenses when dealing with these cases should be carefully considered.

Klaus Weber is an ophthalmic consultant based in Mannheim, Germany. He indicates no financial interest in any product mentioned herein. He can be reached by E-mail:


1. W. Schrader, H. Witschel. Ophthalmologe 1994 91:490-97.

2. P.C. Jacobi, et al. Ophthalmology 2001 108:1375-1380.

Related Videos
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
Eric Donnenfeld, MD, a corneal, cataract and refractive surgeon at Ophthalmic Consultants of Connecticut, discusses his ARVO presentation with Ophthalmology Times
John D Sheppard, MD, MSc, FACs, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Osamah Saeedi, MD, MS, at ARVO 2024
© 2024 MJH Life Sciences

All rights reserved.